Reference number : 172-2020-2021-Q3-957288, amendment number : 1, agreement type : C, recipient legal name : Providence Therapeutics Holdings Inc., recipient country : CA, recipient province : AB, recipient city : Calgary|Calgary, recipient postal code : T2Z 3P4, program name english : Industrial Research Assistance Program – Contributions to Firms, program name french : Programme d’aide à la recherche industrielle – Contributions aux entreprises, program purpose english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, program purpose french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, agreement title english : COVID-19 VI Providence, agreement title french : COVID-19 - Providence VI, agreement number : 957288, agreement value : 4700000.0, agreement start date : 2020-09-01, agreement end date : 2021-08-31, description english : Providence Therapeutics, Canada’s leading mRNA vaccine manufacture, is manufacturing an mRNA vaccine against COVID-19. The company is in the R&D phases to demonstrate the preclinical and clinical efficacy of PTX-COVID19-B., description french : Providence Therapeutics, le principal fabricant canadien de vaccins à ARNm du Canada, fabrique un vaccin à ARNm contre la COVID-19. L'entreprise est en phase de R-D pour démontrer l'efficacité préclinique et clinique du PTX-COVID19-B., expected results english : The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization, expected results french : Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation, additional information english : This agreement has been amended 1 time(s). The total amended value is 4,700,000 dollars., additional information french : Cet accord a été modifié 1 fois La valeur totale des modifications est de  4 700 000 dollars., owner organization : nrc-cnrc, owner organization title : National Research Council Canada | Conseil national de recherches Canada